Meningiomas are the most frequently occurring primary tumors within the central nervous system [1], and their biological diversity results in significant differences in treatment strategies and prognosis. Ki-67, a nuclear protein, is actively expressed during cell cycle phases such as G1, S, G2, and M, representing active cell division. During these phases, Ki-67 levels gradually increase, reflecting active cell proliferation, whereas it remains absent in the quiescent G0 phase. In meningiomas, …